PDCD1 and neoplasm: In this regard, immune checkpoint inhibitor (ICI) therapy aims to obstruct the interaction between T-cell surface-expressed PD-1 and its ligand, PD-L1, expressed by the tumor cell to enhance the host’s immunity against tumor cells [60,61].